#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...
pharmatimes.com/news/smc-app...
SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes
The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not
pharmatimes.com
April 7, 2025 at 11:12 AM